This pharmaceutical company develops oral medications for neurological disorders like migraines and epilepsy. Their therapies aim to provide patients with more sustainable treatment options for generalized epilepsies, migraines, and acute repetitive seizures.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals suffering from migraines and epilepsy do not achieve adequate relief from currently available therapies, and a significant percentage experience drug resistance. Current treatments may also have undesirable side effects, tolerability issues, and potential for drug-drug interactions.
Solution
Epalex is a clinical-stage pharmaceutical company developing oral medications with unique mechanisms of action for treating migraines and epilepsy. Their drug candidates, EP102 for migraine and EP103 for epilepsy, are designed to overcome resistance to existing therapies while minimizing side effects. Epalex utilizes a proprietary delivery technology to improve the bioavailability of its drug candidates, substantially increasing the Cmax and AUC compared to standard tablets. EP102 impacts migraine by modulating the inhibitory action of the neurotransmitter gamma aminobutyric acid (GABA A) on GABA A receptors and may be involved in the inhibition of cortical spreading depression. EP103 is a broad-spectrum antiseizure agent that has demonstrated dose-related efficacy in preclinical studies, delaying seizure onset in chemically induced seizures.
Target Audience
The primary target audience includes individuals with migraines or epilepsy who are not adequately treated by current therapies, as well as clinicians seeking new treatment options with differentiated mechanisms of action.
Features
- EP102: Oral dosage form for acute treatment of migraine headache pain and migraine-related symptoms.
- EP102: Modulates GABA A receptors and may inhibit cortical spreading depression.
- EP103: Oral formulation for controlling seizure disorders resistant to available therapies.
- EP103: Demonstrated dose-related delay in seizure onset in preclinical studies.
- Proprietary delivery technology improves bioavailability by increasing Cmax and AUC.
- EP102 has completed a Phase 1a study establishing a well-characterized pharmacokinetic and safety profile.
- EP103 delivers therapeutic levels of an FDA-approved drug that has shown activity in controlling seizures in off-label use.